The Positive Relationship Between Androgen Receptor Splice Variant-7 Expression and the Risk of Castration-resistant Prostate Cancer: A Cumulative Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Mar 3

PMID 36865799

Authors

Shankun Zhao

Jian Liao

Shilong Zhang

Maolei Shen

Xin Li

Libo Zhou

Affiliations

Soon will be listed here.

Abstract

Background: At present, androgen deprivation therapy (ADT) is still the standard regimen for patients with metastatic and locally advanced prostate cancer (PCa). The level of androgen receptor splice variant-7 (AR-V7) in men with castration-resistant prostate cancer (CRPC) has been reported to be elevated compared with that in patients diagnosed with hormone-sensitive prostate cancer (HSPC).

Aim: Herein, we performed a systematic review and cumulative analysis to evaluate whether the expression of AR-V7 was significantly higher in patients with CRPC than in HSPC patients.

Methods: The commonly used databases were searched to identify the potential studies reporting the level of AR-V7 in CRPC and HSPC patients. The association between CRPC and the positive expression of AR-V7 was pooled by using the relative risk (RR) with the corresponding 95% confidence intervals (CIs) under a random-effects model. For detecting the potential bias and the heterogeneity of the included studies, sensitivity analysis and subgroup analysis were performed. Publication bias was assessed Egger's and Begg's tests. This study was registered on PROSPERO (ID: CRD42022297014).

Results: This cumulative analysis included 672 participants from seven clinical trials. The study group contained 354 CRPC patients, while the other group contained 318 HSPC patients. Pooled results from the seven eligible studies showed that the expression of positive AR-V7 was significantly higher in men with CRPC compared to those with HSPC (RR = 7.55, 95% CI: 4.61-12.35, < 0.001). In the sensitivity analysis, the combined RRs did not change substantially, ranging from 6.85 (95% CI: 4.16-11.27, < 0.001) to 9.84 (95% CI: 5.13-18.87, < 0.001). In the subgroup analysis, a stronger association was detected in RNA hybridization (RISH) measurement in American patients, and those studies were published before 2011 (all < 0.001). There was no significant publication bias identified in our study.

Conclusion: Evidence from the seven eligible studies demonstrated that patients with CRPC had a significantly elevated positive expression of AR-V7. More investigations are still warranted to clarify the association between CRPC and AR-V7 testing.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022297014.

Citing Articles

The Role of CENPK Splice Variant in Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.

Huang M, Qin S, Gao H, Kim W, Xie F, Yin P Cells. 2024; 13(19.

PMID: 39404386 PMC: 11475995. DOI: 10.3390/cells13191622.

Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.

Waseem M, Wang B Int J Mol Sci. 2024; 25(2).

PMID: 38256166 PMC: 10816550. DOI: 10.3390/ijms25021093.

References

Welti J, Nava Rodrigues D, Sharp A, Sun S, Lorente D, Riisnaes R . Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016; 70(4):599-608. PMC: 5015575. DOI: 10.1016/j.eururo.2016.03.049. View

Li H, Zhang Y, Li D, Ma X, Xu K, Ding B . Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol. 2021; 79(6):879-886. DOI: 10.1016/j.eururo.2021.01.037. View

Di Lorenzo G, Zappavigna S, Crocetto F, Giuliano M, Ribera D, Morra R . Assessment of Total, PTEN, and AR-V7 Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. Clin Genitourin Cancer. 2021; 19(5):e286-e298. DOI: 10.1016/j.clgc.2021.03.021. View

Lu C, Luo J . Decoding the androgen receptor splice variants. Transl Androl Urol. 2014; 2(3):178-186. PMC: 4209743. DOI: 10.3978/j.issn.2223-4683.2013.09.08. View

Hornberg E, Ylitalo E, Crnalic S, Antti H, Stattin P, Widmark A . Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One. 2011; 6(4):e19059. PMC: 3084247. DOI: 10.1371/journal.pone.0019059. View

Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O . Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell. 2006; 10(4):309-19. DOI: 10.1016/j.ccr.2006.08.021. View

Saylor P, Lee R, Arora K, Deshpande V, Hu R, Olivier K . Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. Clin Cancer Res. 2016; 23(2):363-369. DOI: 10.1158/1078-0432.CCR-16-0237. View

El Kharraz S, Dubois V, van Royen M, Houtsmuller A, Pavlova E, Atanassova N . The androgen receptor depends on ligand-binding domain dimerization for transcriptional activation. EMBO Rep. 2021; 22(12):e52764. PMC: 8647150. DOI: 10.15252/embr.202152764. View

Kanayama M, Lu C, Luo J, Antonarakis E . AR Splicing Variants and Resistance to AR Targeting Agents. Cancers (Basel). 2021; 13(11). PMC: 8197115. DOI: 10.3390/cancers13112563. View

10.

Linja M, Savinainen K, Saramaki O, Tammela T, Vessella R, Visakorpi T . Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001; 61(9):3550-5. View

11.

Saad F, de Bono J, Barthelemy P, Dorff T, Mehra N, Scagliotti G . Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. Eur Urol. 2022; 83(4):352-360. DOI: 10.1016/j.eururo.2022.05.030. View

12.

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson P, True L . Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One. 2011; 6(11):e27970. PMC: 3219707. DOI: 10.1371/journal.pone.0027970. View

13.

Taplin M, Bubley G, Shuster T, FRANTZ M, Spooner A, Ogata G . Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995; 332(21):1393-8. DOI: 10.1056/NEJM199505253322101. View

14.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

15.

Lopez J, Anazco-Guenkova A, Monteagudo-Garcia O, Blanco S . Epigenetic and Epitranscriptomic Control in Prostate Cancer. Genes (Basel). 2022; 13(2). PMC: 8872343. DOI: 10.3390/genes13020378. View

16.

Tolkach Y, Kremer A, Lotz G, Schmid M, Mayr T, Forster S . Androgen Receptor Splice Variants Contribute to the Upregulation of DNA Repair in Prostate Cancer. Cancers (Basel). 2022; 14(18). PMC: 9496991. DOI: 10.3390/cancers14184441. View

17.

Bogemann M, Shore N, Smith M, Tammela T, Ulys A, Vjaters E . Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. Eur Urol. 2022; 83(3):212-221. DOI: 10.1016/j.eururo.2022.07.018. View

18.

Lu C, Brown L, Antonarakis E, Armstrong A, Luo J . Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. Prostate Cancer Prostatic Dis. 2020; 23(3):381-397. PMC: 7725416. DOI: 10.1038/s41391-020-0217-3. View

19.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

20.

Scher H, Beer T, Higano C, Anand A, Taplin M, Efstathiou E . Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375(9724):1437-46. PMC: 2948179. DOI: 10.1016/S0140-6736(10)60172-9. View